Symbols / INDP $1.75 +9.37% Indaptus Therapeutics, Inc.

Healthcare • Biotechnology • United States • NCM
INDP Chart
About

Indaptus Therapeutics, Inc., a clinical biotechnology company, engages in the development of various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate consists of Decoy20, which is used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, as well as for the treatment of advanced solid tumors. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York.

Fundamentals
Scroll to Statements
Sector Healthcare Industry Biotechnology Market Cap 3.92M
Enterprise Value -4.91M Income -20.85M Sales —
Book/sh 1.45 Cash/sh 3.79 Dividend Yield —
Payout 0.00% Employees 5 IPO —
P/E — Forward P/E -1.26 PEG —
P/S — P/B 1.21 P/C —
EV/EBITDA 0.25 EV/Sales — Quick Ratio 1.38
Current Ratio 1.51 Debt/Eq — LT Debt/Eq —
EPS (ttm) -21.58 EPS next Y -1.39 EPS Growth —
Revenue Growth — Earnings 2026-03-17 16:00 ROA -148.91%
ROE -5.88% ROIC — Gross Margin 0.00%
Oper. Margin 0.00% Profit Margin 0.00% Shs Outstand 2.24M
Shs Float 1.18M Short Float 0.73% Short Ratio 0.34
Short Interest — 52W High 19.91 52W Low 1.51
Beta 0.99 Avg Volume 54.17K Volume 203.49K
Target Price $10.00 Recom None Prev Close $1.60
Price $1.75 Change 9.37%
Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$10.00
Mean price target
2. Current target
$1.75
Latest analyst target
3. DCF / Fair value
$-65.50
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.75
Low
$10.00
High
$10.00
Mean
$10.00

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2024-11-13 main Maxim Group Buy → Buy $5
2024-10-16 reit HC Wainwright & Co. Buy → Buy $12
2024-06-17 reit HC Wainwright & Co. Buy → Buy $12
2024-04-15 reit HC Wainwright & Co. Buy → Buy $12
2023-09-20 reit HC Wainwright & Co. Buy → Buy $12
2023-08-15 reit HC Wainwright & Co. Buy → Buy $12
2023-08-11 reit HC Wainwright & Co. Buy → Buy $12
2023-08-08 reit HC Wainwright & Co. Buy → Buy $12
2023-05-04 reit HC Wainwright & Co. — → Buy $12
2023-03-20 main HC Wainwright & Co. — → Buy $12
2023-03-08 reit HC Wainwright & Co. — → Overweight $15
2023-02-08 reit HC Wainwright & Co. — → Buy $15
2021-10-19 up Maxim Group Hold → Buy $16
News
RSS: Latest INDP news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-01-20 BEN-TZVI AVRAHAM Director — 25,000 $0.00 $0
2025-12-22 MECKLER JEFFREY A Chief Executive Officer — 216,617 $2.03 $439,733
2025-12-22 LINSCOTT WALT ADDISON ESQ. Chief Operating Officer — 54,421 $2.03 $110,475
2025-12-22 SASSI NIR Chief Financial Officer — 26,758 $2.03 $54,319
2025-12-22 NEWMAN MICHAEL JAMES Officer and Director — 52,204 $2.03 $105,974
2025-07-25 MECKLER JEFFREY A Chief Executive Officer — 6,068 $8.30 $50,379
2024-11-25 MECKLER JEFFREY A Chief Executive Officer — 42,553 $1.18 $50,000
2024-08-08 MECKLER JEFFREY A Chief Executive Officer — 84,932 $1.82 $155,001
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.00
0.00
0.00
0.00
Operating Revenue
0.00
0.00
0.00
0.00
Operating Expense
19.83
+29.08%
15.37
-6.18%
16.38
+9.84%
14.91
Research And Development
9.34
+28.82%
7.25
-4.86%
7.62
+20.51%
6.32
Selling General And Administration
10.49
+29.30%
8.11
-7.33%
8.76
+1.99%
8.59
General And Administrative Expense
10.49
+29.30%
8.11
-7.33%
8.76
+1.99%
8.59
Other Gand A
10.49
+29.30%
8.11
-7.33%
8.76
+1.99%
8.59
Total Expenses
19.83
+29.08%
15.37
-6.18%
16.38
+9.84%
14.91
Operating Income
-19.83
-29.08%
-15.37
+6.18%
-16.38
-9.84%
-14.91
Total Operating Income As Reported
-19.83
-29.08%
-15.37
+6.18%
-16.38
-9.84%
-14.91
EBITDA
-19.83
-29.08%
-15.37
+6.18%
-16.38
-9.85%
-14.91
Normalized EBITDA
-19.83
-29.08%
-15.37
+6.18%
-16.38
-9.85%
-14.91
Reconciled Depreciation
0.00
-100.00%
0.00
-42.76%
0.00
-27.91%
0.00
EBIT
-19.83
-29.08%
-15.37
+6.18%
-16.38
-9.84%
-14.91
Net Income
-20.85
-38.79%
-15.02
+2.60%
-15.42
-7.68%
-14.32
Pretax Income
-20.85
-38.79%
-15.02
+2.60%
-15.42
-7.68%
-14.32
Net Non Operating Interest Income Expense
—
—
—
0.59
Net Interest Income
—
—
—
0.59
Interest Income Non Operating
—
—
—
0.59
Interest Income
—
—
—
0.59
Other Income Expense
-1.02
-395.41%
0.34
-64.01%
0.96
+62.39%
0.59
Other Non Operating Income Expenses
-1.02
-395.41%
0.34
-64.01%
0.96
+62.39%
0.59
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-20.85
-38.79%
-15.02
+2.60%
-15.42
-7.68%
-14.32
Net Income From Continuing Operation Net Minority Interest
-20.85
-38.79%
-15.02
+2.60%
-15.42
-7.68%
-14.32
Net Income From Continuing And Discontinued Operation
-20.85
-38.79%
-15.02
+2.60%
-15.42
-7.68%
-14.32
Net Income Continuous Operations
-20.85
-38.79%
-15.02
+2.60%
-15.42
-7.68%
-14.32
Normalized Income
-20.85
-38.79%
-15.02
+2.60%
-15.42
-7.68%
-14.32
Net Income Common Stockholders
-20.85
-38.79%
-15.02
+2.60%
-15.42
-7.68%
-14.32
Diluted EPS
—
-45.08
+12.02%
-51.24
-5.78%
-48.44
Basic EPS
—
-45.08
+12.02%
-51.24
-5.78%
-48.44
Basic Average Shares
—
0.33
+11.36%
0.30
+1.68%
0.30
Diluted Average Shares
—
0.33
+11.36%
0.30
+1.68%
0.30
Diluted NI Availto Com Stockholders
-20.85
-38.79%
-15.02
+2.60%
-15.42
-7.68%
-14.32
Line Item Trend 2023-12-31
Total Assets
14.92
Current Assets
14.00
Cash Cash Equivalents And Short Term Investments
13.36
Cash And Cash Equivalents
13.36
Other Short Term Investments
0.00
Receivables
—
Other Receivables
—
Prepaid Assets
0.63
Assets Held For Sale Current
—
Total Non Current Assets
0.93
Net PPE
0.17
Gross PPE
0.17
Properties
0.00
Buildings And Improvements
0.17
Other Properties
0.17
Non Current Prepaid Assets
0.75
Other Non Current Assets
0.75
Total Liabilities Net Minority Interest
2.85
Current Liabilities
2.77
Payables And Accrued Expenses
1.46
Payables
0.85
Accounts Payable
0.81
Current Accrued Expenses
0.61
Pensionand Other Post Retirement Benefit Plans Current
1.21
Total Tax Payable
0.04
Current Debt And Capital Lease Obligation
0.10
Current Capital Lease Obligation
0.10
Total Non Current Liabilities Net Minority Interest
0.07
Long Term Debt And Capital Lease Obligation
0.07
Long Term Capital Lease Obligation
0.07
Stockholders Equity
12.08
Common Stock Equity
12.08
Capital Stock
0.08
Common Stock
0.08
Preferred Stock
0.00
Share Issued
0.30
Ordinary Shares Number
0.30
Treasury Shares Number
0.00
Additional Paid In Capital
57.41
Retained Earnings
-45.42
Gains Losses Not Affecting Retained Earnings
0.00
Other Equity Adjustments
—
Total Equity Gross Minority Interest
12.08
Total Capitalization
12.08
Working Capital
11.22
Invested Capital
12.08
Total Debt
0.18
Capital Lease Obligations
0.18
Net Tangible Assets
12.08
Tangible Book Value
12.08
Preferred Stock Equity
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-14.82
-20.29%
-12.32
+8.07%
-13.41
-2.50%
-13.08
Cash Flow From Continuing Operating Activities
-14.82
-20.29%
-12.32
+8.07%
-13.41
-2.50%
-13.08
Net Income From Continuing Operations
-20.85
-38.79%
-15.02
+2.60%
-15.42
-7.68%
-14.32
Depreciation Amortization Depletion
0.00
-100.00%
0.00
-42.76%
0.00
-27.91%
0.00
Depreciation
0.00
-100.00%
0.00
-42.76%
0.00
-27.91%
0.00
Depreciation And Amortization
0.00
-100.00%
0.00
-42.76%
0.00
-27.91%
0.00
Other Non Cash Items
—
—
-0.43
-291.80%
-0.11
Stock Based Compensation
1.36
-41.10%
2.31
-22.26%
2.97
+0.29%
2.96
Operating Gains Losses
—
—
—
-0.02
Gain Loss On Investment Securities
—
—
—
-0.11
Unrealized Gain Loss On Investment Securities
1.15
0.00
—
—
Change In Working Capital
3.51
+795.89%
0.39
+175.71%
-0.52
+67.22%
-1.58
Change In Prepaid Assets
0.67
+914.32%
-0.08
-150.65%
0.16
-45.19%
0.30
Change In Payables And Accrued Expense
2.85
+500.95%
0.47
+169.66%
-0.68
+41.07%
-1.15
Change In Payable
2.85
+500.95%
0.47
+169.66%
-0.68
+41.07%
-1.15
Change In Account Payable
2.85
+500.95%
0.47
+169.66%
-0.68
+41.07%
-1.15
Change In Other Working Capital
-0.00
-1500.70%
0.00
-78.05%
0.00
-32.67%
0.00
Change In Other Current Assets
—
—
0.00
+100.00%
-0.72
Investing Cash Flow
—
0.00
-100.00%
17.14
+204.34%
-16.43
Cash Flow From Continuing Investing Activities
—
0.00
-100.00%
17.14
+204.34%
-16.43
Net PPE Purchase And Sale
—
—
—
0.00
Purchase Of PPE
—
—
—
0.00
Capital Expenditure
—
—
—
—
Net Investment Purchase And Sale
—
0.00
-100.00%
17.14
+203.26%
-16.60
Purchase Of Investment
—
0.00
+100.00%
-6.86
+76.83%
-29.60
Sale Of Investment
—
0.00
-100.00%
24.00
+84.62%
13.00
Net Other Investing Changes
—
—
—
0.17
Financing Cash Flow
17.54
+269.51%
4.75
0.00
0.00
Cash Flow From Continuing Financing Activities
17.54
+269.51%
4.75
0.00
0.00
Net Issuance Payments Of Debt
5.71
0.00
—
—
Issuance Of Debt
5.71
0.00
—
—
Long Term Debt Issuance
5.71
0.00
—
—
Net Long Term Debt Issuance
5.71
0.00
—
—
Net Common Stock Issuance
6.40
+16.08%
5.51
0.00
0.00
Proceeds From Stock Option Exercised
0.00
0.00
—
0.00
Net Other Financing Charges
-0.57
+25.34%
-0.76
—
—
Changes In Cash
2.72
+135.92%
-7.58
-302.81%
3.74
+112.66%
-29.51
Beginning Cash Position
5.79
-56.69%
13.36
+38.80%
9.63
-75.40%
39.13
End Cash Position
8.51
+47.02%
5.79
-56.69%
13.36
+38.80%
9.63
Free Cash Flow
-14.82
-20.29%
-12.32
+8.07%
-13.41
-2.50%
-13.08
Interest Paid Supplemental Data
—
—
—
—
Income Tax Paid Supplemental Data
—
0.00
+0.00%
0.00
-33.33%
0.00
Common Stock Issuance
6.40
+16.08%
5.51
0.00
0.00
Issuance Of Capital Stock
12.40
+124.96%
5.51
0.00
0.00
Net Preferred Stock Issuance
6.00
0.00
—
—
Preferred Stock Issuance
6.00
0.00
—
—
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category